Collagen Corporation

Cohesion Technologies, Inc.

Baxter International Inc.

Baxter Healthcare Sa

Gore Enterprise Holdings, Inc.

Angiotech Pharmaceuticals (us), Inc.

Angiodevice International Gmbh

Other

Angiotech Pharmaceuticlas (us), Inc.

Woonza Rhee

Donald G. Wallace

Alan S. Michaels

Louis Fries

Ramon A., Jr. Burns

Hanne Bentz

Woonza M Rhee

Frank A DeLustro

Richard A Berg

Donald G Wallace

Alan S Michaels

Ramon A Burns, Jr

George H Chu

Jacqueline Anne Schroeder

Prema R Rao

Hans Christian Hedrich

Joris Hoefinghoff

Atsushi Edward Osawa

Joel S Rosenblatt

Naomi Sakai

Carol F Harner

Thomas L Smestad

Larry J Braga

Cary J Reich

Lilip Lau

William M Hartigan

A Edward Osawa

Charles T Maroney

Felix Vega

Gregory M Cruise

Jacqueline A Tefft

George T Coker, Iii

Marcee M Maroney

Kimberly A McCullough

Kimberly McCullough

Abigail Freeman

Olof Mikael Trollsas

Jeffrey Eric Yeung

Dan M Jolivette

Ramesh Damani

Frank A Delustro

Jr Burns Ramon A

Frank Delustro

Edward A Osawa

The present invention provides a hemostatic composite sponge comprising oxidized cellulose and an essentially gelatin-free bioadhesive material stably associated with said sponge and present in an organized pattern on said sponge.

Hemostatic sponge

The present invention provides a hemostatic composite sponge comprising a porous matrix of a biomaterial and a bioadhesive material stably associated with said sponge and present in an organized pattern on said sponge.

The present invention provides a hemostatic composite sponge comprising a porous matrix of a biomaterial and a material enhancing the adherence of said sponge to the applied tissue stably associated with at least one surface of said sponge, a method of producing these sponges and their use in hemostasis.

Compositions, methods, and kits are provided for sealing applications. Compositions are prepared by combining a first cross-linkable component with a second cross-linkable component to form a porous matrix having interstices, and combining the porous matrix with a hydrogel-forming component to fill at least some of the interstices. The compositions exhibit minimal swelling properties.

Rapidly acting dry sealant and methods for use and manufacture

Provided are crosslinked polymer compositions that include a first synthetic polymer containing multiple nucleophilic groups covalently bound to a second synthetic polymer containing multiple electrophilic groups. The first synthetic polymer is preferably a synthetic polypeptide or a polyethylene glycol that has been modified to contain multiple nucleophilic groups, such as primary amino (&#x2014;NH) or thiol (&#x2014;SH) groups. The second synthetic polymer may be a hydrophilic or hydrophobic synthetic polymer, which contains or has been derivatized to contain, two or more electrophilic groups, such as succinimidyl groups. The compositions may further include other components, such as naturally occurring polysaccharides or proteins (such as glycosaminoglycans or collagen) and/or biologically active agents. Also disclosed are methods for using the crosslinked polymer compositions to effect adhesion between a first surface and a second surface; to effect tissue augmentation; to prevent the formation of surgical adhesions; and to coat a surface of a synthetic implant.

Method for treating or inhibiting the formation of adhesions following surgery or injury

Method for preventing the formation of adhesions following surgery or injury

Crosslinked polymer compositions comprise a first synthetic polymer containing multiple nucleophilic groups covalently bound to a second synthetic polymer containing multiple electrophilic groups. The first synthetic polymer is preferably a synthetic polypeptide or a polyethylene glycol that has been modified to contain multiple nucleophilic groups, such as primary amino (&#x2014;NH)or thiol (&#x2014;SH) groups. The second synthetic polymer may be a hydrophilic or hydrophobic synthetic polymer which contains, or has been derivatized to contain, two or more electrophilic groups, such as succinimidyl groups. The compositions may further comprise other components, such as naturally occurring polysaccharides or proteins (such as glycosaminoglycans or collagen) and/or biologically active agents. Also disclosed are methods for using the crosslinked polymmer compositions to effect adhesion between a first surface and a second surface; to effect tissue augmentation; to prevent the formation of surgical adhesions; and to coat a surface of a synthetic implant.

Biocompatible crosslinked composition

Crosslinked polymer compositions

The present invention discloses novel crosslinked biomaterial compositions which are prepared using hydrophobic polymers as a crosslinking agent. Preferred hydrophobic polymers are those that contain two or more reactive succinimidyl groups, including disuccinimidyl suberate, bis(sulfosuccinimidyl)suberate, and dithiobis(succinimidyl)propionate. Crosslinked biomaterial compositions prepared using mixtures of hydrophobic and hydrophilic crosslinking agents are also disclosed. The compositions of the present invention can be used to prepare formed implants for use in a variety of medical applications.

Use of hydrophobic crosslinking agents to prepare crosslinked biomaterial compositions

Synthetic implant with nonimmunogenicity coating

The present invention discloses novel crosslinked biomaterial compsotions which are prepared using hydrophobic polymers as a crosslinking agent. Preferred hydrophobic polymers are those that contain two or more reactive succinimidyl groups, including disuccinimidyl suberate, bix(sulfosuccinimidyl) suberate, and dithiobis(succinimidylpropionate). Crosslinked biomaterial compositions prepared using mixtures of hydrophobic and hydrophilic crosslinking agents are also disclosed. The compositions of the present invention can be used to prepare formed implants for use in a variety of medical applications.

Crosslinkable biomaterial compositions containing hydrophobic and hydrophilic crosslinking agents

Composition for administration of a biologically active compound

A method is provided for the rapid formation of a biocompatible gel, and may be carried out in situ, i.e., at a selected site within a patient's body. The method involves admixing a biocompatible crosslinking component A having m sulfhydryl groups wherein m&gE;2 and a biocompatible crosslinking component B having n sulfhydryl-reactive groups wherein n&gE;2 and m&plus;n>4, wherein the sulfhydryl-reactive groups are capable of covalent reaction with the sulfhydryl groups upon admixture of the components under effective crosslinking conditions to form a gel in less than one minute. Suitable reaction conditions for carrying out the crosslinking reaction will depend on the particular components and the type of reaction involved; that is, the &ldquo;effective crosslinking conditions&rdquo; may involve reaction in bulk or in a solvent, addition of a base, and/or irradiation of the admixture in the presence of a free radical initiator. Exemplary uses include tissue augmentation, biologically active agent delivery, bioadhesion, and prevention of adhesions following surgery or injury. Reactive gel-forming compositions and systems are also provided.

Rapid-gelling biocompatible polymer composition and associated methods of preparation and use

Growing community of inventors

Palo Alto, CA, United States of America

Woonza M Rhee